KE3874A - Improvements in or relating to novel difluoro antiviral agents - Google Patents

Improvements in or relating to novel difluoro antiviral agents

Info

Publication number
KE3874A
KE3874A KE3874A KE387489A KE3874A KE 3874 A KE3874 A KE 3874A KE 3874 A KE3874 A KE 3874A KE 387489 A KE387489 A KE 387489A KE 3874 A KE3874 A KE 3874A
Authority
KE
Kenya
Prior art keywords
relating
antiviral agents
novel difluoro
difluoro
novel
Prior art date
Application number
KE3874A
Other languages
English (en)
Inventor
Larry Wayne Hertel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23881409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KE3874(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of KE3874A publication Critical patent/KE3874A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/02—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Furan Compounds (AREA)
KE3874A 1983-03-10 1989-04-12 Improvements in or relating to novel difluoro antiviral agents KE3874A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/473,883 US4526988A (en) 1983-03-10 1983-03-10 Difluoro antivirals and intermediate therefor
EP84301463A EP0122707B1 (en) 1983-03-10 1984-03-06 Improvements in or relating to novel difluoro antiviral agents

Publications (1)

Publication Number Publication Date
KE3874A true KE3874A (en) 1989-06-30

Family

ID=23881409

Family Applications (1)

Application Number Title Priority Date Filing Date
KE3874A KE3874A (en) 1983-03-10 1989-04-12 Improvements in or relating to novel difluoro antiviral agents

Country Status (36)

Country Link
US (5) US4526988A (enEXAMPLES)
EP (1) EP0122707B1 (enEXAMPLES)
JP (2) JPS59175498A (enEXAMPLES)
KR (1) KR860001283B1 (enEXAMPLES)
AR (1) AR243533A1 (enEXAMPLES)
AT (1) ATE29726T1 (enEXAMPLES)
AU (1) AU565856B2 (enEXAMPLES)
BG (1) BG40814A3 (enEXAMPLES)
CA (2) CA1218647A (enEXAMPLES)
CS (1) CS246075B2 (enEXAMPLES)
CY (1) CY1489A (enEXAMPLES)
DD (1) DD216468A5 (enEXAMPLES)
DE (2) DE19675003I2 (enEXAMPLES)
DK (2) DK162529C (enEXAMPLES)
ES (1) ES8602840A1 (enEXAMPLES)
FI (1) FI77870C (enEXAMPLES)
GB (2) GB2136425B (enEXAMPLES)
GR (1) GR81845B (enEXAMPLES)
HK (1) HK44989A (enEXAMPLES)
HU (1) HU193893B (enEXAMPLES)
IE (1) IE57071B1 (enEXAMPLES)
IL (2) IL71143A (enEXAMPLES)
KE (1) KE3874A (enEXAMPLES)
LU (1) LU88791I2 (enEXAMPLES)
MX (1) MX9203246A (enEXAMPLES)
MY (1) MY102025A (enEXAMPLES)
NL (1) NL950018I2 (enEXAMPLES)
NZ (1) NZ207358A (enEXAMPLES)
PH (2) PH23240A (enEXAMPLES)
PL (1) PL142437B1 (enEXAMPLES)
PT (1) PT78181B (enEXAMPLES)
RO (1) RO89963A (enEXAMPLES)
SG (1) SG21889G (enEXAMPLES)
SU (1) SU1442076A3 (enEXAMPLES)
UA (1) UA5955A1 (enEXAMPLES)
ZA (1) ZA841605B (enEXAMPLES)

Families Citing this family (245)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ZA859008B (en) * 1984-12-04 1987-07-29 Lilly Co Eli The treatment of tumors in mammals
IL77133A (en) * 1984-12-04 1991-01-31 Lilly Co Eli Antineoplastic pharmaceutical compositions containing pentofuranoside derivatives,some new such compounds and their preparation
CA1295998C (en) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides and their use as antineoplastic agents
US4681873A (en) * 1985-07-29 1987-07-21 Warner-Lambert Company 4-amino-3-halo-2-pyridinone nucleoside and nucleotide compounds
US4814438A (en) * 1986-12-24 1989-03-21 Eli Lilly And Company Immunoglobulin conjugates of 2',2'-difluronucleosides
US4994558A (en) * 1986-12-24 1991-02-19 Eli Lilly And Company Immunoglobulin conjugates
IL84842A0 (en) * 1986-12-24 1988-06-30 Lilly Co Eli Immunoglobulin conjugates
EP0277599A3 (en) * 1987-01-30 1990-05-09 Asahi Glass Company Ltd. Fluorine containing cyclopentane derivatives and processes for their production
CA1340645C (en) * 1987-04-17 1999-07-13 Victor E. Marquez Acid stable dideoxynucleosides active against the cytopathic effects of human immunodeficiency virus
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
IL87517A (en) 1987-08-28 1993-05-13 Lilly Co Eli Process for preparing an enantiomeric mixture of erythro and threo lactones
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
EP0329348B1 (en) * 1988-02-16 1995-07-12 Eli Lilly And Company 2',3'-Dideoxy-2',2'-difluoronucleosides
US4983724A (en) * 1988-02-16 1991-01-08 Eli Lilly And Company Inversion of 2,2-difluororibose to a 2,2-difluoroxylose and intermediates therefor
US5644043A (en) * 1988-02-16 1997-07-01 Eli Lilly And Company 2',3'-dideoxy-2',2'-difluoronucleosides and intermediates
KR0138996B1 (ko) * 1988-03-16 1998-04-30 레이몬드 에이치. 칸 치환된 아데닌 유도체 및 이를 함유하는 약제학적 조성물
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
JPH0232093A (ja) * 1988-06-08 1990-02-01 Merrell Dow Pharmaceut Inc 抗レトロウィルスジフルオロ化ヌクレオシド類
US4987224A (en) * 1988-08-02 1991-01-22 University Of Georgia Research Foundation, Inc. Method of preparation of 2',3'-dideoxynucleosides
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
US4954623A (en) * 1989-03-20 1990-09-04 Eli Lilly And Company Recovery of difluoro sugar
CA2012129A1 (en) * 1989-03-20 1990-09-20 Ramakrishnan Nagarajan Recovery of difluoro sugar
US5401861A (en) * 1992-06-22 1995-03-28 Eli Lilly And Company Low temperature process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
YU43193A (sh) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
US5401838A (en) * 1992-06-22 1995-03-28 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
BR9302427A (pt) * 1992-06-22 1994-01-11 Lilly Co Eli Processo estereo seletivo para a preparacao de um derivado de riboturanosila
US5594124A (en) * 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5256798A (en) * 1992-06-22 1993-10-26 Eli Lilly And Company Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
US5371210A (en) * 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5252756A (en) * 1992-06-22 1993-10-12 Eli Lilly And Company Process for preparing beta-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl-arylsulfonates
US5606048A (en) * 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5426183A (en) * 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en) * 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5256797A (en) * 1992-06-22 1993-10-26 Eli Lilly And Company Process for separating 2-deoxy-2,2-difluoro-D-ribofuranosyl alkylsulfonate anomers
PL299413A1 (en) * 1992-06-22 1994-03-07 Lilly Co Eli Stereoselective glycozilation process effected by means o anions
US5424416A (en) * 1993-08-25 1995-06-13 Eli Lilly And Company Process for preparation of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonates and their use in preparation of 2',2'-difluoro-2'-deoxy nucleosides
US5480992A (en) * 1993-09-16 1996-01-02 Eli Lilly And Company Anomeric fluororibosyl amines
US5428176A (en) * 1994-04-14 1995-06-27 Eli Lilly And Company Process for preparing 2,2-difluoroketene silyl O,S-acetals and α,α-difluoro-β-silyloxy-1,3-dioxolane-4-propanoic acid O,S-esters
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) * 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
US5559222A (en) * 1995-02-03 1996-09-24 Eli Lilly And Company Preparation of 1-(2'-deoxy-2',2'-difluoro-D-ribo-pentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose
CA2171518A1 (en) * 1995-03-24 1996-09-25 Douglas Patton Kjell Process for the preparation of 2,2'-anhydro- and 2' -keto-1-(3', 5'-di-o-protected-.beta.-d-arabinofuranosyl) nucleosides
US5633367A (en) 1995-03-24 1997-05-27 Eli Lilly And Company Process for the preparation of a 2-substituted 3,3-difluorofuran
US6001994A (en) * 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
AU1289697A (en) 1995-12-13 1997-07-03 Eli Lilly And Company Alpha, alpha-difluoro-beta-hydroxy thiol esters and their synthesis
US5756775A (en) * 1995-12-13 1998-05-26 Eli Lilly And Company Process to make α,α-difluoro-β-hydroxyl thiol esters
US5808020A (en) * 1996-08-12 1998-09-15 Associated Universities, Inc. Optical reaction cell and light source for 18F! fluoride radiotracer synthesis
US6013790A (en) * 1996-09-25 2000-01-11 Board Of Regents University Of Nebraska-Lincoln Heavily fluorinated sugar analogs
JP2001518931A (ja) * 1997-03-24 2001-10-16 イーライ・リリー・アンド・カンパニー ジフルオロヌクレオシドホスホン酸とその誘導体
DE69933860T2 (de) 1998-02-25 2007-05-31 Emory University 2'-fluoronukleoside
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
AU9598601A (en) * 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
AU2002365256A1 (en) * 2001-10-25 2003-07-30 Eli Lilly And Company Gemcitabine in the treatment of smallpox
EP1465615B1 (en) * 2002-01-15 2012-08-01 Trustees of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
WO2003068162A2 (en) * 2002-02-14 2003-08-21 Pharmasset Ltd. Modified fluorinated nucleoside analogues
WO2004080462A1 (ja) * 2003-03-10 2004-09-23 Eisai Co., Ltd. c-Kitキナーゼ阻害剤
EP1631278A4 (en) * 2003-05-20 2006-09-20 Aronex Pharmaceuticals Inc COMBINED CHEMOTHERAPY COMPRISING CAPECITABINE AND A COMPLEX BASED ON LIPOSOMIC PLATINUM
AU2003239510A1 (en) * 2003-05-20 2005-01-21 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising gemcitabine and a liposomal platinum complex
PL3521297T3 (pl) * 2003-05-30 2022-04-04 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydów
US20060034943A1 (en) * 2003-10-31 2006-02-16 Technology Innovations Llc Process for treating a biological organism
WO2005044788A1 (ja) * 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
ES2389809T3 (es) 2004-02-06 2012-10-31 Threshold Pharmaceuticals, Inc. Terapias anticancerosas
AU2005222384A1 (en) * 2004-03-05 2005-09-22 Vegenics Limited Growth factor binding constructs materials and methods
US20050249667A1 (en) * 2004-03-24 2005-11-10 Tuszynski Jack A Process for treating a biological organism
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
PT1773856E (pt) * 2004-07-21 2012-05-14 Gilead Pharmasset Llc Preparação de 2-desoxi-2-fluoro-d-ribofuranosilo pirimidinas e purinas substituídas com alquilo e seus derivados
KR100578616B1 (ko) * 2004-07-23 2006-05-10 한미약품 주식회사 Ｄ-에리트로-2,2-다이플루오로-2-데옥시-1-옥소라이보스화합물의 제조방법
CA2574954C (en) * 2004-07-29 2010-04-20 Hanmi Pharm. Co., Ltd. 1-.alpha.-halo-2,2-difluoro-2-deoxy-d-ribofuranose derivatives and process for the preparation thereof
WO2006015346A1 (en) * 2004-07-30 2006-02-09 Pharmaessentia Corp. STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
NZ554442A (en) 2004-09-14 2011-05-27 Pharmasset Inc Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
US20060089328A1 (en) * 2004-10-22 2006-04-27 Edgar Schridde Ready-to-use gemcitabine solutions
US7563570B2 (en) * 2004-10-29 2009-07-21 Pangaea Biotech Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
CA2586687A1 (en) * 2004-12-08 2006-06-15 Sicor Inc. Difluoronucleosides and process for preparation thereof
CN101080417B (zh) * 2004-12-17 2011-01-19 伊莱利利公司 吉西他滨的酰胺前体药物、其组合物以及应用
BRPI0606480A (pt) 2005-01-21 2008-03-11 Astex Therapeutics Ltd compostos farmacêuticos
GEP20094822B (en) * 2005-03-04 2009-11-10 Dabur Pharma Ltd Intermediate and process for preparing of beta- anomer enriched 21-deoxy, 21, 21-difluoro-d-ribofuranosyl nucleosides
WO2006119347A1 (en) * 2005-05-02 2006-11-09 Pharmaessentia Corp. STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
AU2011202539B2 (en) * 2005-06-03 2012-07-05 Scinopharm Taiwan, Ltd. Process of making an alpha-anomer enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl sulfonate and use thereof for making a beta nucleoside
AU2006255706B2 (en) * 2005-06-03 2011-06-23 Scinopharm Taiwan, Ltd. Process of making an alpha-anomer enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl sulfonate and use thereof for making a beta nucleoside
KR20080035630A (ko) 2005-07-18 2008-04-23 바이파 사이언스 인코포레이티드 암의 치료
AT502221A1 (de) * 2005-07-20 2007-02-15 Pharmacon Forschung & Beratung Gmbh Homogemcitabine, verfahren zu ihrer herstellung sowie deren verwendung
US20100105031A1 (en) * 2005-08-01 2010-04-29 Esai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
WO2007015257A2 (en) * 2005-08-04 2007-02-08 Hetero Drugs Limited A process for the preparation of gemcitabine using novel intermediates
KR100990590B1 (ko) * 2005-09-01 2010-10-29 에자이 알앤드디 매니지먼트 가부시키가이샤 붕해성이 개선된 의약 조성물의 제조 방법
EP1940859A1 (en) 2005-10-28 2008-07-09 Arch Pharmalabs Limited An improved process for preparation of gemcitabine hydrochloride
WO2007052850A1 (ja) 2005-11-07 2007-05-10 Eisai R & D Management Co., Ltd. 血管新生阻害物質とc-kitキナーゼ阻害物質との併用
EP1964837A4 (en) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Antitumor agent against multiple myeloma
US20090281301A1 (en) * 2005-12-14 2009-11-12 Dong-A-Pharm.Co Ltd Manufacturing Process of 2' ,2' - Difluoronucleoside and Intermediate
US20090069557A1 (en) * 2006-02-06 2009-03-12 Dr. Reddy's Laboratories Ltd. Preparation of gemcitabine
CA2641719A1 (en) * 2006-02-07 2007-08-16 Chemagis Ltd. Process for preparing gemcitabine and associated intermediates
US20070249823A1 (en) * 2006-04-20 2007-10-25 Chemagis Ltd. Process for preparing gemcitabine and associated intermediates
AU2007252506C1 (en) * 2006-05-18 2012-07-19 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
JPWO2008001956A1 (ja) * 2006-06-29 2009-12-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝線維症治療剤
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
KR100741310B1 (ko) * 2006-08-01 2007-08-01 (주) 유일팜테크 젬시타빈의 합성에 유용한 신규한나프탈렌-2-카르복실레이트 유도체와 그의 제조방법
EP2065372B1 (en) * 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
SI2845866T1 (sl) 2006-10-27 2017-07-31 Genentech, Inc. Protitelesa in imunokonjugati in njihove uporabe
CA2670099A1 (en) * 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
WO2008064132A2 (en) * 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
CN101616671A (zh) 2007-01-19 2009-12-30 卫材R&D管理有限公司 胰腺癌治疗用组合物
WO2008093855A1 (ja) * 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
EP2139884B1 (en) * 2007-03-23 2013-12-04 Dongwoo Syntech Co., Ltd. Process for preparing of 2'-deoxy-2'2'-difluorocytidine
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN101024667B (zh) * 2007-03-30 2011-01-26 湖北益泰药业有限公司 盐酸吉西他宾的合成方法
US8765690B2 (en) * 2007-04-05 2014-07-01 Threshold Pharmaceuticals, Inc. Treatment of cancer with glufosfamide in patients not receiving insulin therapy
US20080262215A1 (en) * 2007-04-23 2008-10-23 Chemagis Ltd. Gemcitabine production process
CN100475832C (zh) * 2007-05-31 2009-04-08 南京卡文迪许生物工程技术有限公司 一种新颖的高立体选择性合成吉西他滨工艺及中间体
EP2173368A1 (en) * 2007-07-18 2010-04-14 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
US20090048205A1 (en) * 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
US20090069354A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched gemcitabine
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
JP4253357B1 (ja) 2007-09-27 2009-04-08 株式会社湯山製作所 手撒き薬剤供給装置、薬剤の手撒き方法、及び、薬剤分包装置
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
KR20100102107A (ko) * 2007-11-06 2010-09-20 파마이센시아 코퍼레이션 β-뉴클레오시드의 새로운 합성 방법
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
JP5809415B2 (ja) 2007-11-09 2015-11-10 ペレグリン ファーマシューティカルズ，インコーポレーテッド 抗ｖｅｇｆ抗体の組成物および方法
AU2008321382A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
ES2718047T3 (es) * 2008-01-11 2019-06-27 Reata Pharmaceuticals Inc Triterpenoides sintéticos y métodos de uso en el tratamiento de la enfermedad
US20100324087A1 (en) * 2008-01-29 2010-12-23 Eisai R&D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
WO2009146218A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
AU2009237579C1 (en) 2008-04-18 2016-05-12 Reata Pharmaceuticals Holdings, LLC Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
CN104250280A (zh) * 2008-04-18 2014-12-31 里亚塔医药公司 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
TW201004627A (en) * 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8350023B2 (en) * 2008-06-12 2013-01-08 ScnioPharm Taiwan, Ltd. Crystalline polymorphs of gemcitabine base
AU2009274037B2 (en) * 2008-07-22 2015-07-09 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
US20110207680A1 (en) * 2008-08-13 2011-08-25 Curd John G Administration of Glufosfamide For The Treatment of Cancer
WO2010049947A2 (en) * 2008-10-28 2010-05-06 Accrete Pharmaceutical Private Limited Preparation of gemcitabine and intermediates thereof
EA019341B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Фосфорамидаты нуклеозидов
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
MX2011006892A (es) 2008-12-23 2011-07-20 Pharmasset Inc Sintesis de nucleosidos de purina.
AR076263A1 (es) * 2009-04-06 2011-06-01 Eisai Inc Composiciones y metodos para tratar cancer. uso.
TWI477508B (zh) * 2009-04-06 2015-03-21 Otsuka Pharma Co Ltd 用以治療癌症之組成物及方法
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
ES2628609T3 (es) * 2009-04-06 2017-08-03 Otsuka Pharmaceutical Co., Ltd. Combinación de fármacos antineoplásicos a base de citidina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
TWI598358B (zh) * 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US20120129799A1 (en) 2009-07-31 2012-05-24 Astron Research Limited stable composition of ready-to-use gemcitabine injection
US8993535B2 (en) 2009-09-04 2015-03-31 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
SG183361A1 (en) 2010-02-18 2012-09-27 Ct Nac Investigaciones Oncologicas Cnio Triazolo [4, 5 - b] pyridin derivatives
DK2547359T3 (en) 2010-03-15 2016-06-06 The Board Of Trustees Of The Univ Of Illionis Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS
JP6058528B2 (ja) 2010-03-31 2017-01-11 ギリアド ファーマセット エルエルシー ヌクレオシドホスホルアミデート
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
WO2011143593A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
WO2011143590A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
JP5898074B2 (ja) 2010-06-25 2016-04-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
EP2619216A4 (en) 2010-09-22 2014-04-02 Alios Biopharma Inc SUBSTITUTED NUCLEOTIDE ANALOG
WO2012069972A1 (en) 2010-11-19 2012-05-31 Piramal Life Sciences Limited A pharmaceutical combination for the treatment of breast cancer
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
WO2012087943A2 (en) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
CN102153602B (zh) * 2011-02-24 2013-11-06 中国农业大学 呋喃糖基修饰的1,3,4-噻二唑衍生物及其制备方法与作为杀菌剂的应用
CN102153601A (zh) * 2011-02-26 2011-08-17 湖南欧亚生物有限公司 一种高选择性的制备盐酸吉西他滨以及其中间体的方法
TW201242597A (en) 2011-03-14 2012-11-01 Piramal Life Sciences Ltd A synergistic pharmaceutical combination for the treatment of pancreatic cancer
EP2694485B1 (en) 2011-04-01 2017-11-15 Genentech, Inc. Combination of akt inhibitor compound and vemurafenib for use in therapeutic treatments
US8765933B2 (en) 2011-04-07 2014-07-01 Pharmaessentia Corp. Asynthesis of β-nucleosides
CA2832449A1 (en) 2011-04-13 2012-10-18 Vinay GIRIJAVALLABHAN 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
MX2013011944A (es) 2011-04-13 2014-05-07 Merck Sharp & Dohme Derivados de nucleosidos 2'-sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
JP6021805B2 (ja) 2011-04-18 2016-11-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CN102453064B (zh) * 2011-06-30 2014-07-09 江苏豪森药业股份有限公司 制备吉西他滨盐酸盐的方法
US9408863B2 (en) 2011-07-13 2016-08-09 Merck Sharp & Dohme Corp. 5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
WO2013009735A1 (en) 2011-07-13 2013-01-17 Merck Sharp & Dohme Corp. 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
AU2012319239B2 (en) 2011-10-03 2017-04-20 Mx Adjuvac Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
CN102417533A (zh) * 2011-10-28 2012-04-18 江苏正大清江制药有限公司 盐酸吉西他滨的合成方法
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
NO2755614T3 (enEXAMPLES) 2012-01-03 2018-03-31
CN104321333A (zh) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 硫代氨基磷酸酯核苷酸前药的固体形式
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
KR101809858B1 (ko) 2012-04-04 2017-12-15 할로자임, 아이엔씨 항-히알루로난 제제 및 종양-표적 탁산을 이용한 병용 치료
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
JP6165848B2 (ja) 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのｄ−アミノ酸化合物
CA2871359A1 (en) 2012-06-08 2013-12-12 F. Hoffmann-La Roche Ag Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
CN104428006B (zh) 2012-07-04 2017-09-08 弗·哈夫曼-拉罗切有限公司 共价连接的抗原‑抗体缀合物
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
KR102001280B1 (ko) 2012-10-08 2019-07-17 아이데닉스 파마슈티칼스 엘엘씨 Hcv 감염에 대한 2'-클로로 뉴클레오시드 유사체
US9757432B2 (en) 2012-11-14 2017-09-12 Ohio State Innovation Foundation Materials and methods useful for treating glioblastorna
CA2889866A1 (en) 2012-12-21 2014-06-26 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
WO2014163558A1 (en) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
ES2687968T3 (es) 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
JP6476591B2 (ja) * 2013-06-05 2019-03-06 セントラル硝子株式会社 （２Ｒ）−２−フルオロ−２−Ｃ−メチル−Ｄ−リボノ−γ−ラクトン類の製造方法
WO2015003747A1 (en) * 2013-07-10 2015-01-15 Asteriapharma Gmbh Composition containing modified derivatives of a cytidine antimetabolite for the treatment of susceptible disease
EP3024490A1 (en) * 2013-07-26 2016-06-01 Threshold Pharmaceuticals, Inc. Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
WO2015066162A1 (en) 2013-10-29 2015-05-07 Otsuka Pharmaceutical Co., Ltd. Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines
WO2015191576A1 (en) 2014-06-09 2015-12-17 Lipomedix Pharmaceuticals Ltd. Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy
CA2947504A1 (en) 2014-06-26 2015-12-30 F. Hoffmann-La Roche Ag Anti-brdu antibodies and methods of use
BR112017002827B1 (pt) 2014-08-28 2023-04-18 Eisai R&D Management Co., Ltd Derivado de quinolina altamente puro e método para produção do mesmo
JP6912386B2 (ja) 2015-01-26 2021-08-04 ザ ユニバーシティー オブ シカゴ 癌特異的なＩＬ１３Ｒα２を認識するＣＡＲ Ｔ細胞
EP3250609A4 (en) 2015-01-26 2018-07-11 The University of Chicago Il13ra alpha 2 binding agents and use thereof in cancer treatment
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
WO2016138026A1 (en) * 2015-02-25 2016-09-01 Ligand Pharmaceuticals, Inc. Gemcitabine derivatives
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
SG11201710198YA (en) 2015-06-16 2018-01-30 Eisai R&D Man Co Ltd Anticancer agent
CA2994925C (en) 2015-08-20 2023-08-29 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
JP6743135B2 (ja) * 2015-09-02 2020-08-19 アッヴィ・インコーポレイテッド 抗ウィルス性テトラヒドロフラン誘導体
AU2015411525B2 (en) * 2015-10-05 2021-08-12 NuCana plc Combination therapy
SMT202100665T1 (it) 2015-12-11 2022-03-21 NuCana plc Sintesi diastereoselettiva di derivati di fosfato e del profarmaco di gemcitabina nuc-1031
MX381890B (es) 2016-03-15 2025-03-13 Oryzon Genomics Sa Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos
US11246905B2 (en) 2016-08-15 2022-02-15 President And Fellows Of Harvard College Treating infections using IdsD from Proteus mirabilis
CN110248673A (zh) 2016-11-21 2019-09-17 百祥制药公司 用于治疗胰腺癌的包括SapC-DOPS的联合疗法
US11034667B2 (en) 2017-01-09 2021-06-15 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
KR102539920B1 (ko) 2017-02-08 2023-06-05 에자이 알앤드디 매니지먼트 가부시키가이샤 종양-치료용 약제학적 조성물
AU2018247767B2 (en) 2017-04-03 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to STEAP-1
CA3061621A1 (en) 2017-04-26 2018-11-01 Thomas I. Kalman Multitargeted nucleoside derivatives
CN110831597A (zh) 2017-05-16 2020-02-21 卫材R&D管理有限公司 肝细胞癌的治疗
TW201912173A (zh) 2017-08-07 2019-04-01 美商安進公司 三陰性乳癌或結腸直腸癌伴隨肝轉移之治療
ES2986343T3 (es) 2017-09-18 2024-11-11 Univ California Anticuerpos contra CLAUDINA-6 y métodos para tratar el cáncer
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
ES2983284T3 (es) 2018-01-09 2024-10-22 Shuttle Pharmaceuticals Inc Inhibidores selectivos de histona deacetilasa para el tratamiento de enfermedades humanas
EP3752511A4 (en) 2018-01-10 2021-12-29 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
KR20200118827A (ko) 2018-02-02 2020-10-16 마베릭스 온콜로지, 잉크. 젬시타빈 모노포스페이트의 소분자 약물 컨쥬게이트
WO2019178433A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
EP3669890A1 (en) 2018-12-18 2020-06-24 Croda International PLC Filamentous nanoparticles having vaccine adjuvant effect
US12171746B2 (en) 2019-01-11 2024-12-24 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
SG11202109986TA (en) 2019-03-20 2021-10-28 Univ California Claudin-6 antibodies and drug conjugates
CN114206934A (zh) 2019-03-20 2022-03-18 加利福尼亚大学董事会 密封蛋白-6双特异性抗体
EP3962945A1 (en) 2019-04-30 2022-03-09 Instituto de Medicina Molecular João Lobo Antunes Rank pathway inhibitors in combination with cdk inhibitors
JP2022538829A (ja) 2019-06-24 2022-09-06 アムジェン インコーポレイテッド 癌治療のためのＳＩＲＰγの阻害
CA3143349A1 (en) 2019-07-17 2021-01-21 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
EP4143199A4 (en) 2020-04-21 2024-07-03 Ligand Pharmaceuticals, Inc. NUCLEOTIDE PRODRUG COMPOUNDS
WO2025019361A1 (en) 2023-07-14 2025-01-23 Modulation Therapeutics, Inc. Scd1 inhibitors for treating hematolymphoid neoplasms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2359208A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha,beta-gamma-butyrolactones and beta-substituted-beta-hydroxy-gamma-butyrolactones and the methods of preparing them
US2359096A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha, beta-gamma-butyrolactones and beta-substituted - beta - hydroxy-gamma-butyrolactones and methods of preparing them
FR1362039A (fr) * 1963-04-17 1964-05-29 Ct D Etudes Experimentales Et Nouveau procédé de préparation du semi-aldéhyde succinique
US3282921A (en) * 1964-06-04 1966-11-01 Syntex Corp Halo-deoxynucleosides and processes for the preparation thereof
US3870700A (en) * 1973-05-29 1975-03-11 Miles Lab 2-halogeno-2-deoxy-5-(substituted)uridines
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4352795A (en) * 1981-01-29 1982-10-05 Warner-Lambert Company 7-β-D-Arabinofuranosyl-7H-pyrrolo[2,3-d]pyrimidine compounds and methods for their production
FI832884L (fi) * 1982-08-17 1984-02-18 Sandoz Ag Desoxiuridinderivat, deras framstaellningsfoerfaranden och anvaendning som farmaceutiska medel
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4625020A (en) * 1983-11-18 1986-11-25 Bristol-Myers Company Nucleoside process
CA1295998C (en) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides and their use as antineoplastic agents

Also Published As

Publication number Publication date
IL80463A (en) 1988-07-31
NL950018I1 (enEXAMPLES) 1995-11-01
AU565856B2 (en) 1987-10-01
US4692434A (en) 1987-09-08
JPH069602A (ja) 1994-01-18
RO89963A (ro) 1986-09-30
GB2136425B (en) 1987-05-13
ES530364A0 (es) 1985-12-01
IE840584L (en) 1984-09-10
GB2136425A (en) 1984-09-19
GB8405805D0 (en) 1984-04-11
DE3466224D1 (en) 1987-10-22
US5118820A (en) 1992-06-02
US5015743A (en) 1991-05-14
DK190590D0 (da) 1990-08-10
GB2172287A (en) 1986-09-17
JPH06102655B2 (ja) 1994-12-14
BG40814A3 (bg) 1987-02-16
IL80463A0 (en) 1987-01-30
PL142437B1 (en) 1987-10-31
KR840007883A (ko) 1984-12-11
CY1489A (en) 1989-12-08
EP0122707A1 (en) 1984-10-24
CS246075B2 (en) 1986-10-16
US4526988A (en) 1985-07-02
PH23593A (en) 1989-09-11
CA1223869A (en) 1987-07-07
UA5955A1 (uk) 1994-12-29
ZA841605B (en) 1985-10-30
IL71143A0 (en) 1984-06-29
DK190590A (da) 1990-08-10
MY102025A (en) 1992-02-29
JPS59175498A (ja) 1984-10-04
AU2537484A (en) 1984-09-13
LU88791I2 (fr) 1996-11-05
HU193893B (en) 1987-12-28
US4808614A (en) 1989-02-28
KR860001283B1 (ko) 1986-09-05
DK114484D0 (da) 1984-02-28
DK162529C (da) 1992-03-30
FI840890L (fi) 1984-09-11
DK162529B (da) 1991-11-11
PT78181A (en) 1984-04-01
FI77870B (fi) 1989-01-31
SG21889G (en) 1989-07-14
ATE29726T1 (de) 1987-10-15
JPH0542438B2 (enEXAMPLES) 1993-06-28
FI840890A0 (fi) 1984-03-06
CA1218647A (en) 1987-03-03
SU1442076A3 (ru) 1988-11-30
EP0122707B1 (en) 1987-09-16
DE19675003I2 (de) 2003-05-22
NZ207358A (en) 1987-03-06
HK44989A (en) 1989-06-09
DK170647B1 (da) 1995-11-20
IE57071B1 (en) 1992-04-22
NL950018I2 (nl) 1997-03-03
PL246601A1 (en) 1985-08-13
MX9203246A (es) 1992-07-31
ES8602840A1 (es) 1985-12-01
DD216468A5 (de) 1984-12-12
GB8610648D0 (en) 1986-06-04
AR243533A1 (es) 1993-08-31
GR81845B (enEXAMPLES) 1984-12-12
DK114484A (da) 1984-09-11
GB2172287B (en) 1987-05-20
IL71143A (en) 1988-07-31
FI77870C (fi) 1989-05-10
PH23240A (en) 1989-06-06
PT78181B (en) 1986-08-05

Similar Documents

Publication Publication Date Title
DE3466224D1 (en) Improvements in or relating to novel difluoro antiviral agents
GB2117703B (en) Improvements in or relating to fire-barriers
GB2125649B (en) Improvements in or relating to rangefinders
IL70075A0 (en) Improvements in or relating to 3-aryl-5-pyrazole derivatives
GB2150570B (en) Novel antiviral agents
HK10588A (en) Improvements in or relating to carriers
GB2151768B (en) Improvements in or relating to combustors
DE3470782D1 (en) Improvements in or relating to cable-and-sleeve connectors
GB8817519D0 (en) Improvements in/relating to ladders
GB2155654B (en) Improvements in or relating to eyeguards
DE3563308D1 (en) Improvements in or relating to wrist supports
SG75889G (en) Improvements in or relating to cyanopyrazole herbicides
GB2126041B (en) Improvements in or relating to rangefinders
GB2145899B (en) Improvements in or relating to telecines
GB8827586D0 (en) Improvements in/relating to velocimeters
GB2122785B (en) Improvements in or relating to counter circuits
GB2134577B (en) Improvements in or relating to roadsigns
GB2118587B (en) Improvements in or relating to structures
GB2100303B (en) Improvements in or relating to cardclothing
GB2144570B (en) Improvements in or relating to display devices
GB2210190B (en) Improvements in or relating to ticketing
GB2146768B (en) Improvements in or relating to surveying techniques
GB2143272B (en) Improvements in or relating to scaffolding
ZW4084A1 (en) Improvements in or relating to hydro-cyclones
GB2179774B (en) Improvements in or relating to prescalers